Sugi Predict

Sugi Predict / Compounds / SCHEMBL491900

SCHEMBL491900

SCHEMBL491900

C[C@@H]1C[C@@H](C)CN(CCCOCCCc2ccc(Cl)cc2)C1

nearest known ligand 0.63

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ HRH3 Q9Y5N1 16/20 0.63
▸ SLC6A2 P23975 2/20 0.63
▸ HRH1 P35367 2/20 0.63
▸ CHRM2 P08172 1/20 0.63
▸ ADRA2C P18825 1/20 0.63
▸ SLC6A4 P31645 1/20 0.63
▸ SLC6A3 Q01959 1/20 0.63
▸ KCNH2 Q12809 1/20 0.63
▸ CACNA1C Q13936 1/20 0.63
▸ SCN5A Q14524 1/20 0.63
▸ SIGMAR1 Q99720 3/20 0.61
▸ CHRM4 P08173 1/20 0.61
▸ HTR2C P28335 1/20 0.61
▸ HTR7 P34969 1/20 0.61
▸ TMEM97 Q5BJF2 1/20 0.61
▸ SMN1; SMN2 Q16637 1/20 0.54
▸ L3MBTL1 Q9Y468 1/20 0.54
▸ MAOB P27338 1/20 0.44
▸ HRH4 Q9H3N8 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL491585 1.00 HRH3 (0.63) HRH3SLC6A2HRH1CHRM2ADRA2C
SCHEMBL491873 1.00 HRH3 (0.63) HRH3SLC6A2HRH1CHRM2ADRA2C
SCHEMBL6052840 0.87 HRH3 (0.64) HRH3SLC6A2HRH1CHRM2ADRA2C
SCHEMBL491586 0.86 HRH3 (0.61) HRH3SIGMAR1SMN1; SMN2
SCHEMBL12741679 0.86 HRH3 (0.61) HRH3SIGMAR1SMN1; SMN2
SCHEMBL491723 0.86 HRH3 (0.61) HRH3SIGMAR1SMN1; SMN2
SCHEMBL5484748 0.86 HRH3 (0.61) HRH3SIGMAR1SMN1; SMN2
SCHEMBL491587 0.86 HRH3 (0.61) HRH3SIGMAR1SMN1; SMN2
SCHEMBL491791 0.85 HRH3 (0.72) HRH3SLC6A2HRH1CHRM2ADRA2C
Pitolisant SCHEMBL6052604 0.83 HRH3 (0.61) HRH3SLC6A2HRH1CHRM2ADRA2C

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1863487-B1 TREATMENT OF SYMPTOMS OF PARKINSON'S DISEASE WITH NON-IMIDAZOLE ALKYLAMINES HISTAMINE H3-RECEPTOR LIGANDS BIOPROJET SOC CIV (FR) 2013-05-29 — — EP claimed
US-20090318433-A1 VERY FAST TIME RESOLVED IMAGING IN MULTIPARAMETER MEASUREMENT SPACE BIOPROJET (FR) 2009-12-24 — — US claimed
US-20090082353-A1 TREATMENT OF EPILEPSY WITH NON-IMIDAZOLE ALKYLAMINES HISTAMINE H3-RECEPTOR LIGANDS BIOPROJET (FR) 2009-03-26 — — US claimed
EP-1428820-B1 Non-imidazole alkylamines as histamine H-3-receptor ligands and their therapeutic applications BIOPROJET SOC CIV (FR) 2006-05-17 — — EP claimed
EP-1100503-B1 NON-IMIDAZOLE ALKYLAMINES AS HISTAMINE H 3?-RECEPTOR LIGANDS AND THEIR THERAPEUTIC APPLICATIONS ILE BIOPROJET SOC CIV (FR) 2004-09-22 — — EP claimed
US-8486947-B2 Treatment of Parkinson's disease, obstructive sleep apnea, dementia with Lewy bodies, vascular dementia with non-imidazole alkylamines histamine H3-receptor ligands BIOPROJET (FR) 2013-07-16 — — US disclosed
US-8106041-B2 Combination product comprising an antagonist or inverse agonist of histamine receptor H3 and an antipsychotic and antidepressant agent, and use thereof for the preparation of a medicament that prevents the adverse effects of psychotropic drugs BIOPROJET (FR) 2012-01-31 — — US disclosed
US-20110281844-A1 NON-IMIDAZOLE ALKYLAMINES AS HISTAMINE H3-RECEPTOR LIGANDS AND THEIR THERAPEUTIC APPLICATIONS SCHWARTZ JEAN-CHARLES (FR) 2011-11-17 — — US disclosed
US-7910605-B2 Non-imidazole alkylamines as histamine H3- receptor ligands and their therapeutic applications SOCIETE CIVILE BIOPROJET (FR) 2011-03-22 — — US disclosed
US-20090318433-A1 VERY FAST TIME RESOLVED IMAGING IN MULTIPARAMETER MEASUREMENT SPACE BIOPROJET (FR) 2009-12-24 — — US disclosed
US-20090082353-A1 TREATMENT OF EPILEPSY WITH NON-IMIDAZOLE ALKYLAMINES HISTAMINE H3-RECEPTOR LIGANDS BIOPROJET (FR) 2009-03-26 — — US disclosed
EP-2000462-A2 Non-imidazole alkylamines as histamine H3-receptor ligands and their therapeutic applications BIOPROJET (FR) 2008-12-10 — — EP disclosed
US-20060247223-A1 Administering tertiary amines, e.g., 3,3-Dimethylbutyl 3-piperidinopropyl ether, 3-Phenylpropyl 3-piperidinopropyl ether, or3-(4-Chlorophenyl)propyl 3-piperidinopropyl ether to treat cognitive disorders such as attention, wakefulness and memory disorders SCHWARTZ JEAN-CHARLES 2006-11-02 — — US disclosed
US-20060210624-A1 Combination product comprising an antagonist or inverse agonist of histamine receptor h<sb>3 </sb>and an antipsychotic and antidepressant agent, and use thereof for the preparation of a medicament that prevents the adverse effects of psychotropic drugs BIOPROJET (FR) 2006-09-21 — — US disclosed
EP-1428820-B1 Non-imidazole alkylamines as histamine H-3-receptor ligands and their therapeutic applications BIOPROJET SOC CIV (FR) 2006-05-17 — — EP disclosed
US-20040220225-A1 central nervous system disorders; Alzheimer's disease; attention deficit disorders; cognition activators; psychological disorders; antidepressants SCHWARTZ JEAN-CHARLES (FR) 2004-11-04 — — US disclosed
EP-1100503-B1 NON-IMIDAZOLE ALKYLAMINES AS HISTAMINE H 3?-RECEPTOR LIGANDS AND THEIR THERAPEUTIC APPLICATIONS ILE BIOPROJET SOC CIV (FR) 2004-09-22 — — EP disclosed
EP-1428820-A1 Non-imidazole alkylamines as histamine H-3-receptor ligands and their therapeutic applications BIOPROJET (FR) 2004-06-16 — — EP disclosed
EP-1100503-A2 NON-IMIDAZOLE ALKYLAMINES AS HISTAMINE H 3?-RECEPTOR LIGANDS AND THEIR THERAPEUTIC APPLICATIONS SOCIETE CIVILE BIOPROJET (FR) 2001-05-23 — — EP disclosed
WO-2000006254-A2 NON-IMIDAZOLE ALKYLAMINES AS HISTAMINE H3-RECEPTOR LIGANDS AND THEIR THERAPEUTIC APPLICATIONS SOCIETE CIVILE BIOPROJET (FR) 2000-02-10 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090318433-A1 VERY FAST TIME RESOLVED IMAGING IN MULTIPARAMETER MEASUREMENT SPACE HRH3, HRH4, HCRTR2 HRH3 1/4885SLC6A2 147/4885HRH1 7/4885
US-20060247223-A1 Administering tertiary amines, e.g., 3,3-Dimethylbutyl 3-piperidinopropyl ether, 3-Phenylpropyl 3-piperidinopropyl ether, or3-(4-Chlorophenyl)propyl 3-piperidinopropyl ether to treat cognitive disorders such as attention, wakefulness and memory disorders HRH3, HRH4, PNMT HRH3 1/4885SLC6A2 309/4885HRH1 8/4885
US-20040220225-A1 central nervous system disorders; Alzheimer's disease; attention deficit disorders; cognition activators; psychological disorders; antidepressants HTR1A, HRH4, HTR1D HRH3 6/4885SLC6A2 96/4885HRH1 7/4885
US-20060210624-A1 Combination product comprising an antagonist or inverse agonist of histamine receptor h<sb>3 </sb>and an antipsychotic and antidepressant agent, and use thereof for the preparation of a medicament that prevents the adverse effects of psychotropic drugs HRH3, HRH4, HRH2 HRH3 1/4885SLC6A2 215/4885HRH1 4/4885
US-20090082353-A1 TREATMENT OF EPILEPSY WITH NON-IMIDAZOLE ALKYLAMINES HISTAMINE H3-RECEPTOR LIGANDS HRH3, HRH4, HRH2 HRH3 1/4885SLC6A2 522/4885HRH1 4/4885
US-20110281844-A1 NON-IMIDAZOLE ALKYLAMINES AS HISTAMINE H3-RECEPTOR LIGANDS AND THEIR THERAPEUTIC APPLICATIONS HRH3, HRH4, HRH2 HRH3 1/4885SLC6A2 941/4885HRH1 4/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.